A61K 40/4211
Cd19 or b4
Official title: {CD19 or B4}
A61K40/4211 (Cd19 or b4) appears on 996 US grants and 2,761 published applications in this corpus.
Search patents in A61K- Granted patents
- 996
- Published applications
- 2,761
- Assignees
- 729
- Inventors
- 4,001
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 6 |
| 2005 | 0 | 2 |
| 2006 | 0 | 2 |
| 2007 | 0 | 2 |
| 2008 | 2 | 1 |
| 2009 | 0 | 4 |
| 2010 | 3 | 0 |
| 2011 | 2 | 8 |
| 2012 | 0 | 5 |
| 2013 | 2 | 12 |
| 2014 | 4 | 17 |
| 2015 | 8 | 26 |
| 2016 | 11 | 48 |
| 2017 | 20 | 73 |
| 2018 | 35 | 145 |
| 2019 | 48 | 166 |
| 2020 | 75 | 256 |
| 2021 | 106 | 330 |
| 2022 | 119 | 367 |
| 2023 | 121 | 330 |
| 2024 | 141 | 390 |
| 2025 | 169 | 326 |
| 2026 | 130 | 244 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof6 Oct 2026US 12,753,221 B2Abelzeta Inc.
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Compositions and methods for selective protein degradation29 Sep 2026US 12,747,272 B2Novartis AG
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Anti-cd19 car t cells for treating b-cell malignancies and autoimmune diseases8 Oct 2026US 2026/0306629 A1
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Multispecific antibodies targeting cd3 and cd228 Oct 2026US 2026/0308255 A1
- Chimeric engulfment receptor molecules and methods of use8 Oct 2026US 2026/0308281 A1Cero Therapeutics Holdings, Inc.
Most cited
By later US patents
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- CD19-specific chimeric T cell receptor231US 7,446,179 B2City of Hope · 2008
- Methods for treatment of cancer216US 8,916,381 B1The Trustees of the University of Pennyslvania · 2014